Surgical Science Sweden AB (SUS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Surgical Science Sweden AB (SUS) has a cash flow conversion efficiency ratio of 0.003x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr15.31 Million ≈ $1.65 Million USD) by net assets (Skr4.55 Billion ≈ $489.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SUS company net worth for the company's overall valuation and market capitalisation.
Surgical Science Sweden AB - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Surgical Science Sweden AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Surgical Science Sweden AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Surgical Science Sweden AB ranked by their cash flow conversion efficiency. Explore cash flow quality index of Surgical Science Sweden AB to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Com2uS Corporation
KQ:078340
|
0.002x |
|
Vivotek Inc
TW:3454
|
0.073x |
|
Xperi Corp
NYSE:XPER
|
0.237x |
|
Orient Cement Limited
NSE:ORIENTCEM
|
-0.027x |
|
What's Cooking Group NV/SA
BR:WHATS
|
0.010x |
|
LINAS AGRO GROUP EO 029
F:YG4
|
0.046x |
|
Politeknik Metal Sanayi ve
IS:POLTK
|
0.228x |
|
Chia Hsin Cement Corp
TW:1103
|
0.008x |
Annual Cash Flow Conversion Efficiency for Surgical Science Sweden AB (2015–2025)
The table below shows the annual cash flow conversion efficiency of Surgical Science Sweden AB from 2015 to 2025. View Surgical Science Sweden AB (SUS) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr4.27 Billion ≈ $459.85 Million |
Skr79.80 Million ≈ $8.59 Million |
0.019x | -34.29% |
| 2024-12-31 | Skr4.83 Billion ≈ $519.64 Million |
Skr137.22 Million ≈ $14.77 Million |
0.028x | -48.18% |
| 2023-12-31 | Skr4.35 Billion ≈ $467.61 Million |
Skr238.29 Million ≈ $25.64 Million |
0.055x | +79.42% |
| 2022-12-31 | Skr4.24 Billion ≈ $455.91 Million |
Skr129.49 Million ≈ $13.93 Million |
0.031x | +180.37% |
| 2021-12-31 | Skr3.59 Billion ≈ $385.81 Million |
Skr39.08 Million ≈ $4.21 Million |
0.011x | -79.95% |
| 2020-12-31 | Skr427.05 Million ≈ $45.96 Million |
Skr23.23 Million ≈ $2.50 Million |
0.054x | -60.43% |
| 2019-12-31 | Skr401.68 Million ≈ $43.23 Million |
Skr55.20 Million ≈ $5.94 Million |
0.137x | +58.62% |
| 2018-12-31 | Skr79.38 Million ≈ $8.54 Million |
Skr6.88 Million ≈ $740.18K |
0.087x | -6.64% |
| 2017-12-31 | Skr85.52 Million ≈ $9.20 Million |
Skr7.94 Million ≈ $854.15K |
0.093x | -84.49% |
| 2016-12-31 | Skr22.40 Million ≈ $2.41 Million |
Skr13.40 Million ≈ $1.44 Million |
0.598x | +56.33% |
| 2015-12-31 | Skr19.60 Million ≈ $2.11 Million |
Skr7.50 Million ≈ $807.12K |
0.383x | -- |
About Surgical Science Sweden AB
Surgical Science Sweden AB (publ) develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquis… Read more